[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579956":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":45,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":20,"overallStatus":31,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT delivered with CBCT-guided online adaptive RT","EXPERIMENTAL","Patients will undergo CT guided online adaptive SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25Gy in 5 fractions ENI to PA nodes (+\u002F- pelvic nodes).",[13],"Radiation: Adaptive radiotherapy using SBRT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Adaptive radiotherapy using SBRT","Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Andrew McPartlin, MD","CONTACT","416-946-4501","4855","andrew.mcpartlin@uhn.ca",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":38,"coordinates":39},"Point",[40,41],-79.39864,43.70643,{"lat":41,"lon":40},[44],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100579956","elective-adaptive-radiation-with-sbrt-for-improved-durability-of-response-100579956",false,"NCT06831032","Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response","A Phase I, Prospective, Single-Arm Feasibility Study: Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response (EASY)","EASY","Inclusion Criteria:\n\n1. Histologically confirmed prostate adenocarcinoma.\n2. Oligorecurrent para-aortic +\u002F- common iliac nodal disease planned for SBRT.\n3. ≤10 involved para-aortic (defined as between L1\u002FL2 interface and L4\u002FL5 interface) +\u002F- common iliac LN on PSMA PET imaging.\n4. ECOG performance status 0-2.\n\nExclusion Criteria:\n\n1. Prior radiotherapy to the nodal echelon (PA +\u002F- common iliac).\n2. Active secondary malignancy, except for adequately treated non-melanoma skin cancer.\n3. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study.\n4. Contraindication to radiation.","MALE","18 Years",{"count":58,"type":59},26,"ESTIMATED","INTERVENTIONAL",[62],"NA","This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and\u002For common iliac nodal disease detected by PSMA PET or conventional CT\u002FMRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.",[65,66,67,68,69],"Prostate Adenocarcinoma","Iliac Nodal Disease","Para-aortic Lymph Node Metastasis","Para-aortic Nodal Disease","Oligorecurrence","2026-03-18",{"date":72,"type":73},"2026-03-23","ACTUAL",{"date":75,"type":59},"2026-07-07",{"date":77,"type":59},"2029-07-07",{"name":5,"class":6},1]